Skip to content

Sarcopenia, Fall and Osteoporosis in Chronic Kidney Disease

Sarcopenia, Fall and Osteoporosis in Patients With Chronic Kidney Disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04515342
Enrollment
140
Registered
2020-08-17
Start date
2021-03-10
Completion date
2026-01-01
Last updated
2024-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia, Chronic Kidney Diseases, Osteoporosis

Keywords

Fall, Chronic kidney disease-mineral and bone disorder (CKD-MBD)

Brief summary

This study is a cross-sectional study that wishes to investigate whether there is an increased incidence of sarcopenia in patients with chronic kidney disease compared to the Danish background population. A possible association between sarcopenia and fall, as well as the incidence of osteoporosis in patients with chronic kidney disease will also be described.

Detailed description

Sarcopenia is a condition diagnosed from different clinical findings such as low muscle mass, low muscle strength and possibly also poor physical performance. In the general population, the risk of fall and bone fracture increases, when sarcopenia is also present. Sarcopenia is known to occur in patients with chronic kidney disease, but whether, and if so, how this differs from the incidence in patients without kidney disease has not previously been described. Patients with chronic kidney disease have a 3 times higher risk of bone fracture compared to the Danish background population, and they also have an increased risk of falls. The association between sarcopenia, risk of falls and osteoporosis in patients with kidney disease is until now sparsely described, and because of this, the investigators want to explore this further in this cross-sectional study.

Interventions

DIAGNOSTIC_TESTDXA

Each participant will undergo one DXA scan

OTHERMuscle strength and function assessment

Each patient will have their muscle strength and function assessed with the measurements of handgrip strength, 10 m gait speed and a 30 s sit-to-stand test. They will also fill out a questionnaire assessing Strength, Assistance in walking, Rise from a chair, Climb stairs, and Falls (SARC-F questionnaire).

OTHERBlood samples

Each patient will undergo a physical examination and also deliver blood samples.

Sponsors

Odense University Hospital
CollaboratorOTHER
Herlev Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
20 Years to 120 Years

Inclusion criteria

* Age ≥20 years * Chronic kidney disease stage 4-5 not on dialysis (nonD) (corresponding to an estimated glomerular filtration rate (eGFR) ≤30 ml/min based on Kidney Disease Improving Global Outcomes (KDIGO) definition and not on dialysis)

Exclusion criteria

* Kidney transplanted * Immobilized/hospitalized for more than 1 week within the last 6 weeks * Active treatment with growth hormone or sex hormone * Known muscle disease * The lack of ability to speak or understand Danish * The lack of ability to give an informed consent * The lack of ability to participate in a clinical study based on the assessment by the local investigator

Design outcomes

Primary

MeasureTime frameDescription
Difference in appendicular lean body massDay 0 (day of study procedure)Difference in appendicular lean body mass between patients with chronic kidney disease and a healthy control group examined in a previous study

Secondary

MeasureTime frameDescription
Difference in appendicular muscle massDay 0 (day of study procedure)Difference in appendicular muscle mass between patients with chronic kidney disease and a healthy control group examined in a previous study
Difference in handgrip strengthDay 0 (day of study procedure)Difference in handgrip strength between patients with chronic kidney disease and a healthy control group examined in a previous study
Difference in gait speedDay 0 (day of study procedure)Difference in gait speed between patients with chronic kidney disease and a healthy control group examined in a previous study
Difference in the incidence of sarcopeniaDay 0 (day of study procedure)Difference in the incidence of sarcopenia between patients with chronic kidney disease and a healthy control group examined in a previous study
Difference in the incidence of osteoporosisDay 0 (day of study procedure)Difference in the incidence of osteoporoses between patients with chronic kidney disease and a healthy control group examined in a previous study
Difference in the tendency to fallDay 0 (day of study procedure)Difference in the tendency to fall between patients with chronic kidney disease and a healthy control group examined in a previous study
The correlation between total lean and appendicular lean body mass, handgrip strength, gait speed, sit-to-stand test, tendency to fall and osteoporosisDay 0 (day of study procedure)The correlation between total lean and appendicular lean body mass, handgrip strength, gait speed, sit-to-stand test, tendency to fall and osteoporosis (T-score \<-2.5 in hip and/or lumbal spine)
Difference in sit-to-stand testDay 0 (day of study procedure)Difference in sit-to-stand test between patients with chronic kidney disease and a healthy control group examined in a previous study

Countries

Denmark

Contacts

Primary ContactSabina C Hauge, MD
sabina.chaudhary.hauge@regionh.dk+45 28965887
Backup ContactDitte Hansen, MD, PhD
ditte.hansen.04@regionh.dk+45 38682056

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026